Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress. 

Hematologists Highlight Notable Insights From the 2025 EHA Congress 

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

OncLive App

Interactive Tools

Biomarker Consortium

Subscribe

Yelena Y. Janjigian, MD, is chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

Videos

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.

PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Health Canada Approves Adjuvant Ribociclib for HR+/HER2– Early Breast Cancer

Evan S. Wu, MD, PhD, is an assistant professor at the University of Hawai’i Cancer Center

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Evan S. Wu, MD, PhD, delves into the one of the most pivotal aspects of designing a successful bridging study: the selection of clinical end points.

Choosing Clinical End Points in China for US Bridging Studies

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

The OncLive Insider app is live!

CME Opportunities

Specialty

OncLive Peer Exchange®

Optimizing Treatment Selection in Liver Cancer

Multidisciplinary Approaches in HCC

Liver Transplant Candidacy in HCC

Resection vs Transplant in HCC: Factors to Consider

Radiofrequency Ablation and Curative Intent in HCC

Locoregional Therapy Options in HCC

HCC: Timing of Locoregional and Systemic Therapies

Dosing Strategies With Sorafenib in HCC

Improving Survival in HCC

Incorporating Regorafenib in the HCC Treatment Landscape

Underlying Cirrhosis in the Second-Line Setting of HCC

Current Understanding With Biomarkers in HCC

Emerging c-MET Inhibitors in HCC

Emerging Multikinase Inhibitors in HCC

Evidence With Checkpoint Inhibition in HCC

The Future of HCC Treatment  

Optimizing Treatment Selection in Liver Cancer

Latest Conference Coverage